Kornimate/medical-research-clean huggingface dataset:
improving depression management through peer support

Conditions: Depression

Summary: we conducted a randomized controlled trial (rct) that compared the effectiveness of a telephone delivered, recovery focused, peer-support intervention to enhanced usual care for va patients with depression.

peer-support interventions have been recommended by prestigious national task forces and incorporated into the va comprehensive mental health strategic plan. patients who cope with longer term depressive symptoms may benefit from these interventions.this study examines the effectiveness of a feasible, scalable mutual peer-support intervention for va patients in depression treatment and will inform leaders who are considering implementing peer-support initiatives. in this study, each study participant (a veteran in treatment for depression) was matched with another participating veteran and the pairs were randomized to enhanced usual care or to the telephone based peer-support intervention (dial-up). all study participants received usual care plus written materials outlining depression self-management strategies, behavioral activation, and recovery. dial-up participants also received: a) a peer-support manual that outlined peer support principles and provided peer discussion topics and b) access to a specialized telephone platform that permited free calls to their partners, ready access to mental health staff for back-up and advice, and recorded tips on depression management. patients were encouraged to call their partners at least once per week during the 6-month intervention period. patient outcomes were assessed at 3, 6, and 12 months following enrollment.

Eligibility criteria:
inclusion criteria: * currently in treatment at ann arbor, detroit, battle creek, or saginaw va or their associated community based outpatient clinics * not receiving formal mental health services or regularly attending mutual self-help programs outside of the va * diagnosis of a depressive disorder in the last 24 months that is confirmed by the relevant clinician * being seen less than bi-weekly by clinicians for psychiatric or substance use disorders * past trial of psychotherapy and/or antidepressant trial * have a current phq-9 scores \> 10 or wsas scores \> 10 * have stable access to and ability to communicate by telephone exclusion criteria: * diagnosis of schizophrenia, schizoaffective disorder, mdd with psychotic features, or bipolar i in the past 24 months. diagnosis of active substance dependence in the past 12 months or substance abuse in the last 6 months * an immediate risk of suicide, requiring hospitalization or urgent evaluation * clinician assessment that participation in the study could have an adverse impact on the patient or his/her partner.

Keywords: peer support quality of life telephone
liquiband versus dermabond versus sutures for closure of surgical wounds

Conditions: Surgical Incisions

Summary: to evaluate the cosmetic outcome, effectiveness, user and subject satisfaction, and safety of liquiband® flex in relation to dermabond advanced™ and conventional sutures for the topical closure of surgical wounds.


Eligibility criteria:
inclusion criteria: * male or female aged 18 or older on day of enrollment * scheduled for surgical procedure by a delegated study surgeon * fresh surgical wound with evenly distributed tension over length of incision * willing and able to sign informed consent * agree to return for 2 week (+/- 7 days) and 3 month (90 days +/- 7 days) post-procedure follow-up visit exclusion criteria: * known sensitivity to cyanoacrylates, formaldehyde or acetone products * wounds in which incision edges are under high tension or not easily apposed (after deep layer suture), or over joints (unless immobilized) * wounds less than 15mm in length * wounds in which haemostasis is not able to be achieved, eg, drain is placed or warfarin level \>2.5 prior to surgery * wounds in which deep closure could not be achieved * surgical procedures involving mucus membranes or eyes * mental incapacity, dementia, or inability to give informed consent * pregnant or nursing * disease related or pharmacologically immuno-compromised
mutation detection of ebus-tbna specimens using ngs

Conditions: Lung Cancer

Summary: the objective of the study was to compare the value of routine gene testing and next-generation sequencing (ngs) in detecting gene mutations of small specimens obtained by endobronchial ultrasound transbronchial needle aspiration (ebus-tbna) and get the knowledge of how many ebus-tbna samples were adequate for ngs.

some gene mutations can direct individualized treatment. the routine gene testing of egfr, ros1 and alk is direct sequencing, reverse transcription quantitative real-time polymerase chain reaction (rt-qpcr) and fluorescent in situ hybridization (fish) or immunohistochemistry (ihc). next-generation sequencing (ngs) is a new technique, which is more sensitive than routine techniques. so we decided to compare the value of gene testing between routine method and ngs in ebus-tbna specimens and get the knowledge of how many ebus-tbna samples were adequate for ngs. the study was designed as a prospective and single center study. seventy patients will be enrolled into the study and the clinical data of the patients, including his smoke history, cancer history, occupation exposure and so on, will be collected and recorded in a case report form. for the patients recruited in the study, the lymph nodes suspected to be malignant will be obtained by ebus-tbna. samples will be sent to pathology department of shanghai chest hospital and will be processed with paraffin-embedded, and for those diagnosed with nonsquamous nsclc, routine gene testing of egfr, ros1 and alk will be performed. and the rest tissues will be extracted with dna and performed gene mutations using ngs for these qualified dna samples.

Eligibility criteria:
inclusion criteria: 1. patients who are suspected with nonsquamous non-small cell lung cancer according to the clinical, lab examination and imaging data and had never been diagnosed as primary lung cancer before will be enrolled into the study. 2. the clinical stage of the patients should be in stage iiia-iv judged by the imaging data and can't receive surgery initially. 4. there exist at least one lesions that can be obtained by ebus-tbna. exclusion criteria: 1. the patient is highly suspected to benign lesion, small cell lung cancer and squamous cell carcinoma according to the clinical data. 2. surgery was considered to be the primary treatment. 3. patients who are diagnosed with lung cancer and received treatment with drugs or recurrent with lung cancer will be excluded. 4. severe cardiopulmonary dysfunction and other indications that can't tolerate bronchoscopy.

Keywords: gene testing endobronchial ultrasound (ebus) next-generation sequencing (ngs) small biopsies
efficacy study of transcranial magnetic stimulation for treatment of obsessive-compulsive disorder

Conditions: Obsessive Compulsive Disorder

Summary: this study aimed at verifying whether sessions of repetitive transcranial magnetic stimulation over a certain brain area (the supplementary motor area) could be useful in the relief of obsessive-compulsive disorder symptoms.

patients were randomly administered either real (n = 12) or sham (n = 10) rtms, once a day, 5 days a week, for 2 weeks. randomization was performed according to a computer-generated schedule. subjects and scale-rater physician were blind to treatment status of individuals. only the rtms administrator was aware of group allocations. treatment response was assessed by self-and clinician-rated scales before treatment, immediately after treatment and 3 months thereafter, with the same examiner following a subject throughout the study. all patients included in the study had failed adequate pharmacological treatment for at least 2 antiobsessional drugs. their prescription drugs were continued without change in dosage regimens throughout the study.

Eligibility criteria:
inclusion criteria: * age 18 to 60 years * diagnosis of obsessive-compulsive disorder (ocd) according to dsm-iv-tr criteria and having ocd of at least moderate severity (ybocs score of 16 or above). exclusion criteria: * subjects with comorbid psychiatric disorders (except depression - ham-d ) or history of drug abuse * significant head injury, or of any neurosurgical procedure * pregnant women * patients with metal implants or illnesses that prevent attendance to sessions * patients with a history of seizure or bearing pacemakers

Keywords: obsessive compulsive disorder transcranial magnetic stimulation treatment
primary vitrectomy for the treatment of retinal detachment in highly myopic

Conditions: Intraocular Pressure,; Postoperative Complications

Summary: purpose: to assess the functional and anatomical outcome of primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment (rrd) in highly myopic eyes with axial length over 30 mm. methods design: retrospective single center series. setting: university hospital. patients: high myopic patients treated with primary vitrectomy without scleral buckling for a rhegmatogenous retinal detachment. outcome measures: anatomical success rate with complete reattachment of the retina without silicone oil tamponade and postoperative best-corrected visual acuity (bcva).


Eligibility criteria:
inclusion criteria: * retinal detachment secondary to peripheral breaks (retinal tears, atrophic retinal hole) * secondary to posterior breaks (mh, pvt). exclusion criteria: retinal detachment secondary to * severe eye injury, * diabetic retinopathy, * retinopathy of prematurity, * uveitis.

Keywords: retinal detachment high myopia macular hole axial length scleral buckling vitrectomy visual acuity fundus examination results
urinary incontinence amongst women with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Urinary Incontinence

Summary: the primary aim of the study is to investigate whether pelvic floor muscle training or cough-suppression therapy reduces symptoms of urinary incontinence amongst women with chronic obstructive pulmonary disease grade 1-4 (mild to very severe disease).

this two-centre study will consist of a randomised controlled trial (rct) with a parallel group design and include two intervention groups and one control group. recruitment and data collection will occur simultaneously at the øht and st. olav's hospital in trondheim. all participants will complete an initial four week general group exercise class (1 hour once a week) prior to randomisation. this intervention will focus on strength exercises (lower limb and upper limb), endurance training, balance training and thorax mobilising exercises. all participants will be examined and complete questionnaires at two occasions; after the initial four weeks general exercise/before intervention, and at 16 weeks post-randomisation. participants will be randomised to either intervention group a (pelvic floor muscle training group), intervention group b (cough-suppression group) or a control group who will receive brief written information about pelvic floor muscle training and cough-suppression, but no other form of regular follow-up or intervention throughout the intervention period.

Eligibility criteria:
inclusion criteria: * copd grade 1-4 * subjective urinary incontinence * ability to perform an active contraction of the pelvic floor muscles exclusion criteria: * unstable copd * more than 4 hospital admissions due to copd in the past twelve months * neurological conditions * previous gynecological surgery
antioxidant supplementation in pregnant women

Conditions: Pregnant Women; Preeclampsia

Summary: the purpose of this study is to investigate the benefit of several micro nutrients of antioxidants (using milk) in a cohort of women with low antioxidant status and the changes in cell-free mrna.

preeclampsia remains one of leading causes of maternal and perinatal mortality and morbidity. despite intensive research, the cause of preeclampsia has not been established. one of the theories is exaggeration of systemic inflammatory that might induce reactive oxygen species (ros). it has been proposed that pregnancy will progress uneventfully if adequate antioxidant exists to buffer ros. the ros can induce endothelial dysfunction which leads to clinical symptoms of hypertension and proteinuria in preeclampsia. several large randomized clinical trials of antioxidant supplementation have concluded that there were no benefits of antioxidants supplementation for prevention of preeclampsia. however, there is limited information about benefits of antioxidants in women with low antioxidant status at early gestation that deprived of the antioxidant most. our aim, therefore, in this study was to assess whether early supplementation with milk enriched with vitamin and mineral, such as cu, zn, mn, fe, carotene, vitamin b6, b12, c, e, selenium, and calcium lowers the risk of preeclampsia in women with low antioxidant status at early gestation.

Eligibility criteria:
inclusion criteria: * pregnant women with 8-12 weeks of gestation exclusion criteria: * known multiple pregnancy * known fetal anomaly * known thrombophilia * known infections and mola hydatidosa * chronic renal failure * uncontrolled hypertension * known placental abnormalities * documented uterine bleeding within a week of screening * uterine malformation * history of medical and metabolic complication such as heart disease or diabetes

Keywords: antioxidant supplementation preeclampsia
efficacy and safety of oral cashew nut immunotherapy in children (cajesito)

Conditions: Allergy;Food; Allergy, Nut

Summary: the objectives of the cajesito study are (i) to assess the tolerance of oral cashew nut immunotherapy, by describing the frequency and severity of allergic reactions during oral cashew nut immunotherapy and (ii )to assess the risk factors for severe allergic reactions during oral cashew nut immunotherapy (predictive factors, associated factors.


Eligibility criteria:
inclusion criteria: * patients under the age of 18 with a proven allergy to cashew nuts and followed in the pediatric allergology unit of the university hospital of nancy. * patients who have received oral cashew nut immunotherapy for at least 18 months as of 02/28/2023 exclusion criteria: * patients who have received oral cashew nut immunotherapy for less than 18 months. * patients lost to follow-up for more than 3 years, i.e. last consultation dating from 2020 or earlier

Keywords: allergy food allergy cashew nut allergy oral immunotherapy pistachio allergy
safety, tolerability and pk of a single iv infusion of 10, 40, and 80 µg/kg xg-102 administered to healthy volunteers

Conditions: Inflammation

Summary: the objective of the study is to investigate safety, tolerability, and pharmacokinetics of xg-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg xg-102 to healthy male volunteers


Eligibility criteria:
inclusion criteria: * healthy male volunteers * age ≥ 18 to ≤ 45 years * bp: 100 - 150 mm hg systolic, 50 - 95 mm hg diastolic and pulse rate: 50 - 100 bpm. * body mass index between 18.5 and 30.0 kg/m2 and body weight in the 50 - 100 kg range. * are able to communicate and co-operate with the investigator and his/her staff * healthy on the basis of medical history, physical examination findings, clinical laboratory test results, vital sign measurements, and digital 12 lead ecg readings * written informed consent obtained * male subjects with partners of childbearing potential have to use adequate contraception during, and for at least the four weeks after administration of study medication. exclusion criteria: * heavy smokers, i.e. more than 10 cigarettes per day * participation in a clinical trial during the previous 4 weeks * loss of 500 ml blood or more during the 3 month period before the screening visit of the study * existence of any surgical or medical condition which might relevantly interfere with the subject safety, the distribution, metabolism or excretion of the drug or the study assessments, i.e. impaired renal or hepatic function, diabetes mellitus, thyroid function abnormalities including abnormal thyroid hormone values in the screening evaluation, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract. * history of alcohol or drug abuse in the last 3 years. * positive results of the drug screening. * clinically significant abnormal laboratory values at the screening or baseline evaluation. * a history of any serious adverse reaction or hypersensitivity to any drug or other medicines * presence or history of any allergy requiring acute or chronic treatment (seasonal allergic rhinitis which requires no treatment may be tolerated). * positive results from serology examination for hbv, hcv, hiv or tuberculosis * history of serious mental disorders. * need of any prescription medication within 30 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug or anticipated need for any concomitant medication during the study. * volunteers who are unwilling to comply with the provisions of this protocol * symptoms of a significant (upon investigator's medical judgment) somatic or mental illness in the two week period preceding drug administration.
a phase 1b study of onl1204 ophthalmic solution in patients with progressing open angle glaucoma

Conditions: Open Angle Glaucoma

Summary: the purpose of this study is to demonstrate the safety and tolerability of onl1204 ophthalmic solution in patients with progressing open angle glaucoma. onl1204 ophthalmic solution is a first-in-class inhibitor of fragment apoptosis stimulator (fas) receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease. apoptosis of retinal ganglion cells is associated with progressive glaucoma. nonclinical data on onl1204 ophthalmic solution suggest that onl1204 ophthalmic solution may inhibit the cell death pathways in these cells.


Eligibility criteria:
inclusion criteria: 1. males and females aged ≥18 years old 2. able and willing to give informed consent and attend study visits 3. controlled intraocular pressure (iop) (≤21 mmhg) in both eyes for all previous 3 visits before screening and at screening in both eyes 4. prior to screening, 3 or more humphrey visual field (hvf) tests (with acceptable reliability standards) or 3 or more optical coherence tomography (oct) studies of the study eye on record 5. open angle glaucoma that is progressing in the study eye 6. hvf 24-2 at screening with acceptable reliability standards and md scores exclusion criteria: considerations for either eye 1. best corrected visual acuity (bcva) at screening of ≤64 letters (snellen equivalent of worse than 20/50) 2. severe open angle glaucoma 3. glaucoma due to non-open angle causes 4. worse than mild non-proliferative diabetic retinopathy considerations for study eye: 5. visual field results suggestive of another disease (eg, altitudinal field defect) 6. evidence of macular edema based on oct imaging and investigator's judgement 7. previous intravitreal (ivt) injections, history of retinal surgery, history of retinal laser 8. cataract surgery within 3 months of screening or yttrium-aluminum-garnet capsulotomy (yag) within 4 weeks of screening 9. anticipated need for surgical or procedural intervention for glaucoma, cataract, posterior capsular opacity, refractive error, or retinal conditions during the study other general exclusion criteria: 10. the requirement for oral carbonic anhydrase inhibitors to control intraocular pressure 11. severe, unstable, or uncontrolled cardiovascular, diabetic, renal, or pulmonary disease, based on investigator's judgement 12. systolic blood pressure \>180 mmhg or diastolic blood pressure \>110 mmhg 13. women who are pregnant, breastfeeding, or contemplating pregnancy during the study period and men who are contemplating contributing sperm for a biologic child during the study period 14. participation in other ophthalmic clinical trials or use of any other investigational drugs or devices in either eye or systemically for 3 months before screening (visit 1)

Keywords: progressing glaucoma
aromatherapy methods in reducing anxiety before breast biopsy

Conditions: Patient Relations, Nurse; Patient Satisfaction; Anxiety State; Breast Cancer

Summary: a breast biopsy is a cause for anxiety for most women when faced with a diagnosis of breast cancer. physiological and psychological effects of breast biopsy may continue in the pre-biopsy and post-biopsy period. the aim of this study is to compare the effectiveness of two different aromatherapy methods applied in reducing anxiety before breast biopsy.

anxiety level was evaluated according to objective criteria by pretesting and posttesting lavender, lavender-mint and odorless (placebo) aromatherapy tablets applied before the biopsy in patients scheduled for breast biopsy. the study was conducted with 135 patients, 90 of whom were in the experimental group and 45 in the control group. patients were randomly assigned to the experimental and control groups according to their sequence numbers. before the biopsy, lavender aromatherapy and lavender-mint aromatherapy tablets were administered to the experimental group, and an odorless (placebo) aromatherapy tablet to the control group. aromatherapy tablets 20 minutes after the procedure. first, a small (approximately 1x 0.5 inch), rectangular, absorbent, self-adhesive tablet containing 2 ml of lavender essential oil (10) was adhered to the patient's shoulder level. research data were collected with the "spielberger state anxiety scale" to determine the level of anxiety before and after breast biopsy.

Eligibility criteria:
inclusion criteria: * over 18 years old * female patients scheduled for breast biopsy (stereotactic biopsy, ultrasound biopsy, magnetic resonance imaging biopsy) * individuals who can speak, understand and communicate in turkish will be included in the study. exclusion criteria: * pregnant and lactating women, * patients who are allergic to plants (lavender/lavender-mint), * patients with a diagnosis of psychiatric illness, migraine, chronic headache or sense of smell * patients who have difficulty breathing through their nose * people who can't smell, who are sensitive to smells or smells * patients with a history of asthma, epilepsy or seizures as a precaution. * patients with active wheezing * patients with cognitive, verbal or hearing problems that may affect communication

Keywords: breast cancer aromatherapy anxiety